Oncology Resource Group

Oncology Competitive Intelligence Leaders

Chronic Lymphocytic Leukemia

Sarah Lockhead, Ph.D.
LEAD ANALYST
Read Bio
Contact

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. The most common form of CLL arises from B-cell lymphocytes, with rarer subtypes including prolymphocytic leukemia (PLL), large granular lymphocyte (LGL) leukemia, and hairy cell leukemia (HCL). Since ibrutinib’s first approvals in 2014, the growing dominance of BTK inhibitors and other key therapies targeting CD20, BCL-2, and PI3K in 1st-line and R/R CLL has increasingly eroded the role of chemoimmunotherapy and other older, less tolerable treatments. Current areas of interest include evaluating combinations of key drug class members, optimal treatment durations and sequencing, and MRD-guided strategies.

Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in chronic lymphocytic leukemia to help guide strategic and tactical commercial development decisions for market participants.

Full Support Package

Medical Conference Coverage:

ONCrg Conference™ reports are best-in-class CI analyses of major congresses because of ONCrg’s unmatched depth and insight in the cancer area. Our deep understanding of the landscape and the time-tested analytical methodology we align to your interests, uniquely position us to provide elite support before, during and after conferences and form valuable opinions about the implications of new data on your pipeline. More...

Medical Conference Coverage:
Competitive Landscape Analysis

Competitive Landscape Analysis:

ONCrg Pipeline Strategies™ delivers cutting-edge reports with profiles across the entire competitive landscape, providing valuable analytics by class and treatment subset for new drugs in Phase II through registration and beyond. Our Presentation and Compendium reports are considered best-in-class, not only because they contain a wealth of practical insight but also because each Quarter they are improved for accuracy and value by completely updating them with new data from conferences and other sources. More...

Monthly Surveillance Reports:

ONCrg Sentinel™ reports provide comprehensive coverage of rapidly evolving scientific, clinical, and commercial activities. Our experts vigilantly monitor multiple secondary and primary sources to evaluate clinical trials, product developments, company activities, and regulatory news and deliver monthly reports with unparalleled insight and CI value. More...

Monthly Surveillance Reports:
Erica Wescott
Senior Account Manager, Hem-Onc
Read Bio
Contact

Expert Advisory Guidance:

ONCrg Advisory™ is an open door for client’s to ask non-proprietary questions in this area. Our experts utilize their comprehensive suite of CI resources and experience to provide extra guidance to complete your projects and inform key decisions. More...


Full Support Package:

ONCrg’s medical conference coverage, competitive landscape research, monthly surveillance, and ad hoc analysis are combined for unmatched, year-round expert CI support.

We earn a wide range of endorsements

“My team here loves the work ONCrg does – we are constantly pulling these reports up for various reasons and they are so AWESOME! Thanks so much!” 

Senior Associate Director, Oncology Field Based Medicine

“Wow, very helpful and nice.  I appreciate the preview of coming attractions!   Thank you very much, helps my story a lot with this unbiased view of the market…”

Director, New Product Planning 

“I have run CI and new products marketing across many therapeutic areas, and have never seen a similar product or frankly one that even comes close in terms of attention to detail, level of depth, true understanding of the analysts and ability to communicate to clients, open lines of communication, etc.“

Director, Business Information

“I have to say, this is one of the best intelligence services I have ever used. You and your team do a great job”

Executive Director, Head of Business Excellence and Operations

“What I value most from ONCrg is the unfiltered unbiased view you give irrespective of what manufacturers say. We love the key implications you put together and why they matter”

Interim Head, Oncology

“As always you guys hit these reports out of the park!!  These are so great…. for the first time I’m not making data slides post conferences so thank you for that!” 

Medical Science Liaison Oncology

“ I really liked your past, present and future perspectives. This is some of the best work I have ever seen from a vendor.” 

VP & Head of Medical & Clinical Affairs

“BRAVO!!  Most comprehensive map that I have reviewed for current SOC; and then every MoA and compound in development.  Very Impressive.  My hat is tipped to your team. I will distribute it across to my team and School is in Session.”

Associate Director, Program Lead II - Oncology

“Our organization is extremely frugal so we always have budget challenges but your value us extremely good and we love working with you so we absolutely want to continue investing in ONCrg.”

Director, Commercial Planning

“These reports are incredibly informative and helpful as we think about our research strategy and drug developments options in these indications. I greatly appreciate you and the ONCrg team’s efforts to generate these reports and summaries.

Director Oncology Discovery

“This is great! Until you’ve tried to attend a conference and make sense of what you saw and heard there, you can’t appreciate how hard it is to do it, so this is a really nice way of distilling the information.”

Competitive Intelligence Lead

“I have been supporting myeloma brand for 3 years. This level of quality is what I am personally looking for and beyond what typical CI vendors can do….I see you have subject matter experts in each therapeutic area.”

Director, Scientific & Competitive Analysis, Global Oncology BU

“ONCrg has really good data and really good analysts, which was not what I found at Big Pharma or Small Pharma”

Senior Director Medical Affairs

“I really appreciate working with you and the great support you have provided over the last couple of years! The internal feedback was quite positive: Very clear and precise statements; nice format – holistic and comprehensive” 

Head Scientific Competitive Intelligence Biopharma R&D

“This is an outstanding summary of ASCO GU! We really appreciate all the detailed summaries and implications provided in this report.  The clear insights your team provide continue to be fantastic! We use your upfront slides to convey complicated information to senior leadership.”

Associate Brand Manager, Global Marketing

“Wow! This is amazing. Literally exactly what I was looking for. Thanks so much!! You’re the best.” 

Associate Scientific Director, Solid Tumors Oncology Global Medical Affairs

“This fully answers my question. This additional information and timely response is also extremely helpful in filling some of the gaps I had as I prepare for upcoming governance meetings.”

Global Commercial Development

“My organization relies so heavily on ONCrg. I’m one of the strongest advocates and will continue to be, not just for conferences but across the board. “Our senior managers absolutely love the competitive landscape diagrams in your Pipeline Strategies reports.”

Scientific Director, Oncology; US Medical Affairs

“I love the tumor specific reports that give me  a lay of the land, are easily digestible. I really appreciate the implications and commentary in each report.”

Vice President, Therapeutic Area Head - Solid Tumor

“I know that many really like what you’re doing…everyone was thankful and found the reports very helpful”

 Senior Manager Market Research

I have always found the ONCrg reports to be valuable and to have evolved in sync with the changing times in oncology (not all vendors have).”

Director, New Product Planning

“The fact that ONCrg got our vaccine right is proof that we have done our research”. Also, there were 3 things I picked up from your vaccine presentation that I didn’t know. Quite helpful.”

Chief Medical Officer

“The way you do implications was exactly how I would like them to be delivered from a company covering them at ESMO” 

Senior Director, Product Strategy & Market Intelligence

“Thank you so much for the Onc-rg reports that your team provides.  These reports are very helpful to the field medical team!”  

Associate Director, Medical Science Liaison - Oncology

“Thanks team, this is making my life easier already”

Global Oncology New Product Planning

“I am quite impressed with the approach that you have taken to developing market assessments based on clinical trials reporting in a variety of settings. I appreciate the access to the meeting trials compendia in my core areas of interest”

Group Medical Director Oncology Clinical Development 

“Thank you for the excellent work that you have delivered and for the wonderful partnership we have enjoyed.”

Head, R&D and Commercial Insights, Global Oncology Franchise

“I find the depth of information and their very succinct explanations to be extremely well written and easy to read, so this would enable me to stay aware of compounds moving up the ladder. Great work”

Senior Manager, Medical Affairs, Medical Communications

“I assume you have many clients, so I really appreciate how you can customize the coverage to our needs, I don’t know how you do it.”

Senior Medical Director, Oncology Medical Affairs - US

“Take the opportunity to check out the “Implications” box on each slide. This agency is excellent at providing valuable context for new data. We will get these reports once a month as well as some really helpful supplementary reports.” 

Head of Global Marketing and Commercial Strategy

“Thanks for the support and fantastic customer service.” 

Ex Dir, Head of Business Intelligence & Commercial Operations

“Thanks for all the ASCO updates in RCC, breast, IO, etc.  They really are terrific and help tremendously with our MA debrief…”

Senior Medical Science Liaison
ALREADY A CLIENT? CLICK HERE TO REGISTER.

    Information and Sample Requests

    To learn more about our reports, services, and CI support, please fill out the form below or call us at 650.485.2626.

    *Please note, we will not share your details outside of our company


    Sarah Lockhead, Ph.D.
    Therapy Area Director, Oncology

    Sarah received her Ph.D. in Chemical and Systems Biology at Stanford. Her unique background encompasses multiple areas of drug development, from preclinical oncology research at Pfizer to drug repurposing at Stanford’s School of Medicine. Her breadth of experience enables her to provide her clients with incisive drug landscape analyses and key insights.

      Contact ONCrg


      Please fill out the form below.

      Erica Wescott
      Senior Account Manager, Hem-Onc

      Erica received her Master of Science in Polymer Chemistry from the University of Oregon, and has over 15 years of experience in the pharmaceutical industry in research, development and manufacturing of oral solid dosage forms and insoluble compounds. Her unique background in analytical chemistry and technical project management combined with client-facing experience brings a keen understanding of the need for providing clients with cutting-edge insights for successful drug development. Erica serves multiple accounts and supports our heme-onc analysts and clients.